Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Tacrolimus 38Cyclophosphamide 27Methotrexate 26Mycophenolic Acid 21Cyclosporine 21Busulfan 21fludarabine phosphate 20Antilymphocyte Serum 20Melphalan 15fludarabine 13Sirolimus 13Methylprednisolone 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 10thymoglobulin 9Stem Cell Transplantation 8Radiotherapy 7ruxolitinib 6Thiotepa 6Rituximab 6Granulocyte Colony-Stimulating Factor 6Prednisone 5Hematopoietic Stem Cell Transplantation 5Filgrastim 5Alemtuzumab 5Transplantation 4Etoposide 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Pentostatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Graft vs Host Disease × axatilimab × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡